Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing ¹⁷⁷Lu-PSMA-617...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer.
• 177Lutetium-Prostate-specific membrane Antigen-617 radioligand therapy (177Lu-PSMA RLT) is a targeted treatment option for mCRPC.
• Identifying prognostic factors is crucial for optimizing treatment strategies and patient outcomes in mCRPC.

Purpose of the Study:

• To determine prognostic factors influencing survival in patients with mCRPC undergoing 177Lu-PSMA RLT.
• To assess the association between pre-treatment blood markers, adverse events, and overall survival (OS).
• To identify independent predictors of survival in this patient cohort.

Main Methods:

• Retrospective analysis of 31 mCRPC patients treated with 177Lu-PSMA RLT.
• Collection of patient demographics, clinical data, and pre-treatment blood markers (e.g., PLR, NLR, AAPR, PNI, HALP, SII).
• Kaplan-Meier survival analysis, log-rank tests, and univariate/multivariate Cox regression were used to identify prognostic factors.

Main Results:

• 74.2% of patients experienced adverse events, with 22.6% having serious events.
• Visceral metastasis, fatigue, anorexia, and nephropathy were significantly associated with poor OS.
• Multivariate analysis confirmed visceral metastasis, fatigue, and nephropathy as independent predictors of survival.

Conclusions:

• Adverse events, particularly visceral metastasis, fatigue, and nephropathy, are significant independent prognostic factors for survival in patients undergoing 177Lu-PSMA RLT.
• These findings highlight the importance of monitoring and managing these factors to improve patient outcomes.
• Further research is warranted to explore the mechanisms behind these associations and develop targeted interventions.